G1 Therapeutics (NASDAQ:GTHX) insider Mark A. Velleca sold 7,500 shares of G1 Therapeutics stock in a transaction dated Monday, April 16th. The shares were sold at an average price of $36.00, for a total transaction of $270,000.00. The sale was disclosed in a legal filing with the SEC, which is available through this link.
G1 Therapeutics stock traded up $4.56 during trading hours on Tuesday, hitting $40.85. The stock had a trading volume of 97,958 shares, compared to its average volume of 208,733. G1 Therapeutics has a 12-month low of $12.04 and a 12-month high of $42.78.
G1 Therapeutics (NASDAQ:GTHX) last announced its quarterly earnings results on Wednesday, February 21st. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.02). research analysts predict that G1 Therapeutics will post -2.47 EPS for the current year.
A number of research analysts recently issued reports on the stock. BidaskClub cut shares of G1 Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, March 29th. Needham & Company LLC lifted their price target on shares of G1 Therapeutics to $42.00 and gave the company a “buy” rating in a research report on Tuesday, March 13th. BTIG Research reaffirmed a “buy” rating and issued a $48.00 target price on shares of G1 Therapeutics in a report on Wednesday, March 7th. JPMorgan Chase reaffirmed an “overweight” rating and issued a $39.00 target price (up from $33.00) on shares of G1 Therapeutics in a report on Tuesday, March 6th. Finally, Cowen reaffirmed a “buy” rating on shares of G1 Therapeutics in a report on Monday, March 5th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $38.20.
Several hedge funds have recently made changes to their positions in the company. Franklin Resources Inc. grew its stake in shares of G1 Therapeutics by 10.1% in the fourth quarter. Franklin Resources Inc. now owns 1,535,616 shares of the company’s stock worth $30,467,000 after acquiring an additional 141,000 shares during the period. BlackRock Inc. grew its position in G1 Therapeutics by 113.5% during the fourth quarter. BlackRock Inc. now owns 745,445 shares of the company’s stock valued at $14,790,000 after buying an additional 396,215 shares during the period. Geode Capital Management LLC grew its position in G1 Therapeutics by 9.3% during the fourth quarter. Geode Capital Management LLC now owns 94,366 shares of the company’s stock valued at $1,872,000 after buying an additional 8,061 shares during the period. Vanguard Group Inc. bought a new stake in G1 Therapeutics during the second quarter valued at approximately $1,291,000. Finally, Alps Advisors Inc. grew its position in G1 Therapeutics by 13.1% during the fourth quarter. Alps Advisors Inc. now owns 31,409 shares of the company’s stock valued at $623,000 after buying an additional 3,643 shares during the period. Hedge funds and other institutional investors own 42.10% of the company’s stock.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.